MedGenesis Therapeutix

MedGenesis Therapeutix

MedGenesis Therapeutix Inc..

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round

N/A

Seed
Total Funding000k
More about MedGenesis Therapeutix
Made with AI
Edit

MedGenesis Therapeutix Inc. is a private Canadian biopharmaceutical holding company dedicated to the commercialization of innovative treatments for serious neurologic diseases, with a primary focus on Parkinson's disease. The company operates in the biopharmaceutical sector, targeting neurodegenerative disorders through cutting-edge research and development. MedGenesis serves patients suffering from severe neurological conditions, aiming to bring advanced therapeutic solutions to market. The business model revolves around developing and commercializing novel treatments, leveraging the expertise of its leadership team, including Dr. Erich Mohr, a renowned expert in neurodegenerative disorders. Revenue is generated through the successful commercialization of these treatments, potentially including partnerships, licensing agreements, and direct sales. MedGenesis is committed to advancing the development of Glial Cell Line Derived Neurotrophic Factor (GDNF), a naturally occurring protein that may regenerate dying brain cells in Parkinson's patients and potentially reverse their condition.

Keywords: biopharmaceutical, neurodegenerative, Parkinson's, commercialization, GDNF, innovative treatments, neurologic diseases, research, development, therapeutic solutions.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo